News

19Mar '20

COVID-19: Atnahs Continues Operations

Basildon (UK), 19 March 2020  – On 11 March 2020 the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. This is a serious health situation and we extend our sympathies to patients and relatives and acknowledge the efforts of healthcare professionals. Our primary concern is the health and safety of…

Read more

19Mar '20

Atnahs Acquires Rights to Rocaltrol®, An Established Brand in Women’s Health

Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company, has acquired the global commercial rights excluding China and Japan for Rocaltrol® (Calcitriol) from F. Hoffmann-La Roche Limited (“Roche”). Rocaltrol® (Calcitriol) is used as an active form of Vitamin D, primarily in the treatment of patients with post-menopausal osteoporosis…

Read more

06Feb '20

Atnahs Buys Takeda Out of License Agreement for Bonviva® in Asia

Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for Bonviva® (Ibandronic acid) in seven selected Asian markets. Bonviva® is used to treat osteoporosis in post-menopausal women. Terms and conditions of the transaction are not disclosed. Founded in 2013, Atnahs has significantly increased its product portfolio since inception through…

Read more

27Jan '20

Atnahs Acquires Rights to Established Hypertension Medicines

Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed an agreement to acquire the global (ex-China, India, Japan and US) commercial rights to a portfolio of Cardiovascular medicines used primarily to treat hypertension – namely, Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose…

Read more

08Aug '19

Triton Completes Acquisition of a Majority Stake in Atnahs

Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed the acquisition of a majority stake of Atnahs, a specialty pharmaceutical business, focussed on the acquisition, development and marketing of mature branded medicines. Terms and conditions of the transaction are not disclosed. About Atnahs Atnahs is a specialty pharmaceutical…

Read more

14Dec '18

Atnahs Acquires Famvir®

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Famvir® from Novartis. Famvir® (famciclovir) is an antiviral used primarily as a treatment for herpes. Amit Patel, Atnahs’ Managing Director, comments, “The acquisition of Famvir® continues our strategy of acquiring and marketing trusted brands, and it reinforces our presence in key…

Read more